Document is current
Any future updates will be listed below
-
Authors
Goins, Aleyah E.
Gomez, Kimberly https://orcid.org/0000-0003-1867-5041
Ran, Dongzhi
Afaghpour-Becklund, Mitra
Khanna, Rajesh https://orcid.org/0000-0002-9066-2969
Alles, Sascha R. A. https://orcid.org/0000-0001-8532-8950
-
Funding
Funding for this research was provided by:
Department of Anesthesiology and Critical Care Medicine, University of New Mexico School of Medicine
National Institute of Neurological Disorders and Stroke (NS098772)
National Institute of Neurological Disorders and Stroke (NS120663)
- License Information
-
More Information
Article History
Received: 21 October 2021
Revised: 6 December 2021
Accepted: 8 December 2021
First Online: 20 January 2022
Declarations
:
: R. Khanna is the co-founder of Regulonix LLC, a company developing non-opioids drugs for chronic pain. In addition, R. Khanna 481 has patents US10287334 (Non-narcotic CRMP2 peptides targeting sodium channels for chronic 482 pain) and US10441586 (SUMOylation inhibitors and uses thereof) issued to Regulonix LLC. R. Khanna is also a co-founder of ElutheriaTx Inc., a company developing gene therapy approaches for chronic pain.
